Xcout Intel
CrossBridge Bio, Inc. competitors & alternatives
The 12 closest competitors and alternatives to CrossBridge Bio, Inc. — ranked by similarity to what CrossBridge Bio, Inc. actually does, not by market-cap band.
Subscribe to see CrossBridge Bio, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About CrossBridge Bio, Inc.
CrossBridge Bio, Inc. is a medical technology and biopharmaceutical company pioneering an approach to deliver the next generation of stable antibody-drug conjugates (ADCs).
CrossBridge Bio, Inc. at a glance
CrossBridge Bio, Inc. is a company headquartered in United States. It has raised at least $25M across the 2 funding rounds on record. Its most recent funding round, Grant, raised $15M in November 2025. Xcout tracks 9 named people at CrossBridge Bio, Inc., including Michael Torres (Chief Executive Officer).
CrossBridge Bio, Inc. leadership
- Michael TorresChief Executive Officer
- Zhiqiang AnPromoter
- Zhiqiang F. AnPromoter
- Kyoji TsuchikamaExecutive Officer
- Michael TorresExecutive Officer
- Damir F. IllichDirector
3 more named people on record for CrossBridge Bio, Inc., with roles, board committees and tenure — see the full roster →
CrossBridge Bio, Inc. funding rounds
At least $25M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $15M | 2 named | |
| Seed | $10.8M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent CrossBridge Bio, Inc. news
Top 12 CrossBridge Bio, Inc. competitors
Ranked by semantic similarity — how close each company is to CrossBridge Bio, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Crossbow Therapeutics is a privately held biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company develops potent antibody therapeutics aimed at expanding treatment options and combating cancer.
Biotechnology
Centrose LLC is a biotechnology company that develops a next-generation antibody-drug conjugate platform known as Extracellular Drug Conjugates (EDCs). These precision medicines target the cell surfaceome by binding multiple extracellular proteins simultaneously without cell internalization or drug release, aiming to create safer and more potent treatments for cancer and drug-resistant tumors.
Biotech
Adcytherix is a clinical-stage biopharmaceutical company that develops next-generation antibody-drug conjugates (ADCs) for oncology. The company combines clinically validated targets with innovative payloads derived from approved cancer drugs to treat resistant cancers and address unmet medical needs.
Biotechnology
VelosBio Inc. is a clinical-stage biopharmaceutical company based in California, United States, focused on developing novel antibody-drug conjugates to transform cancer treatment for patients.
Close match by what they do
BrickBio, Inc. is a Boston-based biotechnology company focused on protein bioconjugation. The company empowers next-generation therapeutics using proprietary platforms such as BrickADCs and Protein Origami.
Biopharmaceuticals
Lifordi Immunotherapeutics, Inc. is a clinical-stage biotechnology company based in Burlington, Massachusetts, focused on developing antibody-drug conjugates (ADCs).
Biotechnology
Cybrexa Therapeutics is a clinical-stage oncology biotechnology company that develops tumor-targeting peptide-drug conjugates (PDCs) for cancer patients. Its proprietary alphalex technology uses a pH-driven approach for antigen-independent, intracellular delivery of anti-cancer agents directly to tumors and metastases.
Close match by what they do
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-drug conjugates to treat cancer.
Drug Discovery
LyncBio Therapeutics is an innovative drug discovery and development company headquartered in Shanghai, China, with research facilities in Suzhou. The firm specializes in the advancement of antibody-drug conjugate (ADC) therapeutics.
Close match by what they do
Amberstone Biosciences, Inc. is an early-stage biotechnology firm that pioneers next-generation tumor-activated immunotherapeutics to discover transformative, safe, and effective treatments.
Biotechnology
Curon Biopharmaceutical is a clinical-stage biotechnology company developing antibody-based medicines, including bispecific antibodies, for cancer and other serious diseases. It serves patients and healthcare providers through the development of therapeutic biologics, with programs intended for oncology and immunology applications.
Biotechnology
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of CrossBridge Bio, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for CrossBridge Bio, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →